Low-molecular-weight heparin reduced symptomatic VTE compared with no treatment (RR 0.68; 95% CI 0.49-0.94), while DOACs and UFH reduced clinically relevant VTE but increased major bleeding.
Meta-Analysis (n=43,840)
Do pharmacologic thromboprophylaxis regimens (LMWH, UFH, DOACs) reduce symptomatic and clinically relevant VTE in adult patients hospitalized for an acute medical illness?
In acutely ill medical inpatients, LMWH, DOACs, and UFH reduce clinically relevant VTE, but DOACs and UFH carry a higher risk of major bleeding compared to LMWH.
Effect estimate: RR 0.68 (95% CI 0.49-0.94)
Importance Pharmacologic thromboprophylaxis is widely used for medical inpatients, but its contemporary benefits remain uncertain for clinically relevant venous thromboembolism (VTE). Objective To evaluate and compare the benefits and risks associated with currently approved in-hospital pharmacologic thromboprophylaxis regimens to prevent symptomatic and clinically relevant VTE and bleeding in acutely ill medical inpatients. Data sources MEDLINE, Embase, Web of Science, and the Cochrane CENTRAL databases were searched until January 31, 2026. Reference lists from retrieved articles and reference literature were also examined. Study Selection Randomized clinical trials that involved adult patients hospitalized for an acute medical illness and compared pharmacologic thromboprophylaxis regimens (low-molecular-weight heparin LMWH, unfractionated heparin UHF, and direct oral anticoagulants DOACs) with no treatment or placebo were selected. Data Extraction and Synthesis Dual independent screening, data extraction, and risk-of-bias assessment were performed. Relative risks (RRs) were pooled using network meta-analyses with random effects. The PRISMA reporting guideline was used. Main Outcomes and Measures The effectiveness outcomes were the risk of confirmed symptomatic VTE, clinically relevant VTE, and any VTE. Safety outcomes were mortality, major bleeding, and clinically relevant nonmajor bleeding. Pairwise and network meta-analyses were computed. Results Among the 22 studies (involving 43 840 patients) included, the 90-day pooled risk of symptomatic VTE was 1.7% (95% CI, 0.6%-4.4%) in the no-treatment group. Compared with no treatment, LMWH was associated with reduced symptomatic VTE risk (RR, 0.68; 95% CI, 0.49-0.94). Point estimates for DOACs (RR, 0.69; 95% CI, 0.36-1.31) and UFH (RR, 0.75; 95% CI, 0.40-1.40) were less than 1, although the results were not statistically significant. LMWH (RR, 0.57; 95% CI, 0.43-0.74), DOACs (RR, 0.58; 95% CI, 0.41-0.82), and UFH (RR, 0.66; 95% CI, 0.45-0.97) were associated with reduced risk of clinically relevant VTE. Using a theoretical conversion rate of asymptomatic into symptomatic VTE, both LMWH and DOACs were associated with decreased risk of symptomatic VTE (RR, 0.63 95% CI, 0.48-0.83 and 0.66 95% CI, 0.44-0.99). DOACs (RR, 2.62; 95% CI, 1.25-5.49) and UFH (RR, 2.33; 95% CI, 1.13-4.79) were associated with an increased risk of major bleeding, compared with no treatment, while LMWH (RR, 1.23; 95% CI, 0.81-1.85) had no association. Mortality was unaffected by the treatment regimens. Conclusions and Relevance In this systematic review and network meta-analysis, DOACs, LMWH, and UFH were associated with reduced clinically relevant VTE in medical inpatients; DOACs and UFH had higher risks of major bleeding than LMWH. Proper selection of patients is critical given the overall low absolute risk of VTE.
Marti et al. (Fri,) conducted a meta-analysis in Acutely ill medical inpatients (n=43,840). Pharmacologic thromboprophylaxis (LMWH, UFH, and DOACs) vs. No treatment or placebo was evaluated on Confirmed symptomatic VTE (RR 0.68, 95% CI 0.49-0.94). Low-molecular-weight heparin reduced symptomatic VTE compared with no treatment (RR 0.68; 95% CI 0.49-0.94), while DOACs and UFH reduced clinically relevant VTE but increased major bleeding.